NCT01243762 2018-08-16A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)Merck Sharp & Dohme LLCPhase 1 Terminated47 enrolled 12 charts
NCT00903006 2015-02-02Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast CancerM.D. Anderson Cancer CenterPhase 1/2 Terminated11 enrolled 6 charts